How to Overcome Hashimotos Hairloss Low Dose Naltrexone and Hashimotos Get the Full Episode Transcript Lets Connect
There doesnt appear to be any active research either
We need well-designed, long-term studies in people taking GLP-1 drugs that: directly measure skeletal muscle (not just lean mass), assess muscle function and mobility, track outcomes over months to years, not weeks, and test mitigation strategies, not just observe loss
Their focus on sustainable solutions means clients can expect not only immediate benefits but also long-term support in maintaining their progress
In pregnant mice given 6, 68, 460, or 760 mcg/kg/day exenatide during fetal organogenesis, skeletal variations associated with slowed fetal growth, including changes in number of rib pairs or vertebral ossifications sites, and wavy ribs were observed at 760 mcg/kg/day, a dose that produced maternal toxicity and yielded systemic exposure 390-times the human exposure resulting from the MRHD of BYETTA based on AUC comparison